Flexion Therapeutics Inc., of Burlington Mass., plans to present a pooled analysis of three phase II/III trials testing Zilretta (FX006), triamcinolone acetonide with a poly lactic-co-glycolic acid matrix, in 586 patients with osteoarthritis knee pain, at PAINWeek 2017 in Las Vegas. The findings showed that patients receiving an injection of Zilretta only used 0.86 daily tablets of rescue medication after 12 weeks, compared to 1.23 tablets for patients who received a saline-placebo injection.